Compass Therapeutics (NASDAQ:CMPX – Get Free Report) and Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.
Analyst Recommendations
This is a breakdown of current recommendations for Compass Therapeutics and Rapport Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Compass Therapeutics | 1 | 0 | 13 | 1 | 2.93 |
| Rapport Therapeutics | 1 | 0 | 8 | 0 | 2.78 |
Compass Therapeutics presently has a consensus price target of $13.00, suggesting a potential upside of 143.90%. Rapport Therapeutics has a consensus price target of $51.40, suggesting a potential upside of 81.95%. Given Compass Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Rapport Therapeutics.
Volatility and Risk
Institutional & Insider Ownership
68.4% of Compass Therapeutics shares are held by institutional investors. 29.8% of Compass Therapeutics shares are held by company insiders. Comparatively, 13.6% of Rapport Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Compass Therapeutics and Rapport Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Compass Therapeutics | $850,000.00 | 1,129.27 | -$66.49 million | ($0.43) | -12.40 |
| Rapport Therapeutics | N/A | N/A | -$111.48 million | ($2.86) | -9.88 |
Compass Therapeutics has higher revenue and earnings than Rapport Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Compass Therapeutics and Rapport Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Compass Therapeutics | N/A | -43.61% | -38.05% |
| Rapport Therapeutics | N/A | -28.85% | -27.27% |
Summary
Compass Therapeutics beats Rapport Therapeutics on 9 of the 13 factors compared between the two stocks.
About Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
About Rapport Therapeutics
Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
